Adaptive COVID-19 Treatment Trial 4 (ACTT-4), NIH

Objective

Goal: To evaluate the clinical efficacy of baricitinib + remdesivir versus dexamethasone + remdesivir as assessed by the mechanical ventilation free survival by Day 29.

• Phase III, randomized, double-blind, placebo-controlled trial.
• Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29.
• Multicenter trial with 100 centers globally and 1500 subject enrollment goal.

Investigator

Diego Lopez de Castilla, MD, EvergreenHealth Infectious Disease Care

Clinical Trial Categories

• COVID-19

Contact

EvergreenHealth Research Services at 425-899-5385
or EvergreenResearch@evergreenhealth.com